awmsg logo



valsartan (Diovan®)


Reference No. 671

Publication date:
31/03/2011


Appraisal information

valsartan (Diovan®) 80 mg film-coated tablet
valsartan (Diovan®) 320 mg film-coated tablet
valsartan (Diovan®) 160 mg film-coated tablet
valsartan (Diovan®) 40 mg film-coated tablet
valsartan (Diovan®) 3 mg/ml oral solution


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Cardiovascular system
NMG meeting date: 13/01/2011
AWMSG meeting date: 16/02/2011
   
   
Submission Type: Limited Submission
Status: Not recommended
Advice No: 0211
Ratification by Welsh Government: 29/03/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Valsartan (Diovan®) tablets are not recommended for use within NHS Wales for the treatment of hypertension in children and adolescents 6 to 18 years of age. The submission contained insufficient evidence for AWMSG to recommend its use.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download